Piramal Pharma has been assigned an Environment, Social and Governance (ESG) rating of 68.5 for the financial year 2024-25 by SES ESG Research Pvt. Ltd. The rating was based on data made available by the company in the public domain for that year.
SES ESG Research conducted the assessment independently and voluntarily, without engagement from Piramal Pharma. The ESG rating reflects the company’s performance in environmental, social, and governance factors as reported by the company itself.
The ESG rating and further details are accessible on the SES ESG website. Additionally, this information has been uploaded on the official website of Piramal Pharma at https://www.piramalpharma.com/.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).